Integer Holdings (NYSE:ITGR) said this week that current CEO Thomas Hook has stepped down as the company’s president and CEO, effective immediately, with Joseph Dziedzic taking over as interim prez & CEO.
Hook will stay on the Frisco, Texas-based company’s board until the company’s 2017 annual meeting of stockholders, but will not seek re-election.
Dziedzic is currently a company director, and previously served as exec VP and CFO for The Brink’s Company from 2009 to 2016, Integer Holdings said. The company said it has initiated a “comprehensive search” for a new prez & CEO.
“It has been an honor to lead Integer for 13 years, the last 11 as CEO. I am proud of what we have accomplished as a team, and I strongly believe that Integer has the strengths and capabilities to continue its growth in our industry. It has been my great privilege to work with dedicated and skilled associates at Integer and with committed customers around the world. I am grateful for the commitment and hard work of the Integer team as we have established our company as a global MDO leader with best in class performance,” Hook said in a prepared release.
“On behalf of the board, we want to thank Tom for his contributions to Integer. Much has been achieved under his leadership, and we wish him continued success in his future endeavors. Given our sound financial footing and the substantial completion of the Lake Region Medical integration, the board and Tom agree that now is the right time to transition leadership for Integer’s next period of growth. We are pleased that Joe Dziedzic will serve as Interim CEO. Joe has been an active and valuable contributor to the Integer Board and has a deep understanding of our business,” board chair Bill Sanford said in a prepared statement.
“I look forward to working with the Integer management team to continue executing our strategy of delivering innovative, cost-effective solutions to our customers while generating profitable growth for our company,” Dziedzic said in a press release.
Former FDA commissioner Robert Califf has become the chair of a new non-profit research organization looking to center projects around the needs of people and their health, according to a post from the National Patient-Centered Clinical Research Network.
The new non-profit group, named The People-Centered Research Foundation, has a goal of “accelerating people-driven research that is faster, more user friendly for patients and providers, and less costly.”
The group lists their goals as “to engage patients, families, research participants, clinicians, scientists, and health system leaders in the design, conduct, dissemination, and implementation of research and analysis that leads to improvements in health and well-being of individuals and populations and the performance of health care delivery systems,” according to the foundation’s website.
Integrity Applications said this week it tapped former-Aventis exec John Graham as its new CEO, board chair and company director, succeeding co-founder Avner Gal. The change went into effect March 20.
The Israeli company also said it tapped Angela Strand as vice chair, while Phil Darivoff will retire from their position on the board and Eran Cohen will step down from his COO position.
“Avner and his team have achieved a remarkable accomplishment with the development of GlucoTrack. I joined Integrity because I wanted to be part of a company with disruptive potential. I look forward to working with the employees and the board to build a global enterprise that fully realizes the value of this important device for diabetic patients, clinicians and shareholders,” CEO John Graham said in a press release.
Life sciences venture capital firm Sofinnova Partners said it has tapped Antoine Papiernik as its new chair, succeeding Denis Lucquin who will stay on as managing partner.
“Passing on the responsibilities of chairman in a partnership is a crucial event, and I have full confidence in Antoine taking on this role. Sofinnova Partners is entering a new phase, and the timing is perfect for this change. Antoine stands out for his investment track record and has become a key personality in the world of venture capital, in Europe as well as in the United States. He is also a talented team leader. Antoine has exactly what it takes to drive Sofinnova Partner’s future development,” Lucquin said in a press release.
“It is a great honor to succeed Denis. In the past ten years, under his chairmanship, we successfully completed the firm’s strategic refocus on its core business: Life Sciences investments. Thanks to our investors’ confidence, we significantly grew our assets under management, which today total more than 1.6 billion euros. Moving forward our vision for Sofinnova Partners entails growing our activity and further strengthening our leading position in Life Sciences investments,” Papiernik said in a prepared statement.
Pavmed (NSDQ:PAVMU) said last week it named Dennis McGrath as its new CFO & exec VP, replacing Richard Fitzgerald. McGrath previously held the position of prez & chief financial officer at skin health medical device company PhotoMedex.
“I am thrilled to welcome Dennis to the PAVmed team as we enter an important phase in our company’s evolution. He is a seasoned medical device industry executive with extensive public company leadership experience, who brings a broad range of skills in corporate finance, business development, corporate strategy, operations and administration. Dennis also brings a proven track record of delivering results and driving shareholder value through numerous public and private financings, merger and acquisitions, joint ventures and licensing deals. We also expect PAVmed to benefit immensely from his strong relationships with members of the finance and investment communities,” CEO & chair Dr. Lishan Aklog said in a press release.
“I am excited to be joining this world-class team. PAVmed has all of the necessary ingredients to accelerate its growth and create significant value for its shareholders over the coming years – a remarkable leadership team with a proven track record, a unique capital-efficient business model, an expanding pipeline of game-changing products and a renowned team of directors and medical advisors,” McGrath said in a prepared release.
Fitzgerald will be seeking opportunities closer to his home state of Pennsylvania, according to the company.